Table 2.
Allele and genotype frequencies of MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms in COVID-19 patients and healthy controls and related association analyses
| SNP | Allele /Genotype | COVID-19 (n = 500) N% |
Healthy controls (n = 500) N% |
OR (95% CI) | P |
|---|---|---|---|---|---|
| MMP9 rs3918242 | T vs. C | 192 (19.2) | 134 (13.4) | 1.53 (1.09–2.15) | 0.013 |
| C (Reference) | 808 (80.8) | 866 (86.6) | - | - | |
| TT vs. CC | 30 (6) | 14 (2.8) | 2.40 (0.95–6.05) | 0.061 | |
| CT vs. CC | 132 (26.4) | 106 (21.2) | 1.40 (0.92–2.12) | 0.113 | |
| TT vs. CT + CC | 30 (6) | 14 (2.8) | 2.21 (0.88–5.53) | 0.088 | |
| TT + CT vs. CC | 162 (32.4) | 120 (24) | 1.51 (1.02–2.24) | 0.037 | |
| CC (Reference) | 338 (67.6) | 380 (76) | - | - | |
| HWE | P = 0.17 | ||||
| MMP3 rs3025058 | G vs. C | 238 (23.8) | 168 (16.8) | 1.54 (1.13–2.11) | 0.006 |
| C (Reference) | 762 (76.2) | 832 (83.2) | - | - | |
| GG vs. CC | 42 (8.4) | 6 (1.2) | 7.78 (2.27–26.6) | 0.001 | |
| GC vs. CC | 154 (30.8) | 156 (31.2) | 1.09 (0.74–1.61) | 0.634 | |
| GG vs. GC + CC | 42 (8.4) | 6 (1.2) | 7.55 (2.22–25.6) | 0.0012 | |
| GG + GC vs. CC | 196 (39.2) | 162 (32.47) | 1.34 (0.92–1.94) | 0.113 | |
| CC (Reference) | 304 (60.8) | 338 (67.6) | - | - | |
| HWE | P = 0.06 | ||||
| MMP2 rs243865 | T vs. C | 212 (21.2) | 204 (20.4) | 1.04 (0.77–1.42) | 0.755 |
| C (Reference) | 788 (78.8) | 796 (79.6) | - | - | |
| TT vs. CC | 24 (4.8) | 18 (3.6) | 1.34 (0.54–3.27) | 0.518 | |
| CT vs. CC | 164 (32.8) | 168 (33.6) | 0.98 (0.67–1.43) | 0.926 | |
| TT vs. CT + CC | 24 (4.8) | 8 (3.6) | 1.35 (0.55–3.26) | 0.505 | |
| TT + CT vs. CC | 188 (37.6) | 186 (37.2) | 1.01 (0.70–1.46) | 0.926 | |
| CC (Reference) | 312 (62.4) | 314 (62.8) | - | - | |
| HWE | P = 0.16 |
SNP, Single nucleotide polymorphism; MMP, Matrix metalloproteinase; COVID-19, Coronavirus disease 2019; OR, Odds ratio; 95% CI, 95% Confidence interval; HWE, Hardy-Weinberg equilibrium